Short answer
PROCEPT BioRobotics Corp (PRCT) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 FY2026 results for quarter ended June 30, 2026, announced August 4, 2026.
PROCEPT BioRobotics Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 FY2026 results for quarter ended June 30, 2026, announced August 4, 2026
- Full financial results furnished in Exhibit 99.1, requiring review for revenue, profitability, and guidance
- Press release not deemed “filed” under Exchange Act Section 18, limiting associated liability exposure
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $94.5M, up 19%, led by U.S. system sales $29.1M, up 32%, and consumables $48.4M, up 12%
- U.S. procedures 13,100, up approximately 21%, with 65 HYDROS placements and ending install base of 816 systems
- Gross margin 66%, aided by pricing and a $2.9M tariff refund, signaling near-term profitability support from commercial execution
- Net loss widened to $26.9M from $19.6M, while adjusted EBITDA loss increased to $11.3M from $8.0M
- 2026 revenue guidance maintained at $390M to $410M, while procedure guidance narrowed to 54,000-56,000 and adjusted EBITDA loss to $30M-$35M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PROCEPT BioRobotics Corp 8-K filings
Get the next PRCT 8-K as it lands
Follow PRCT for push alerts, or ask the research agent what this filing means.